Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Xenical TV Ads Shifting Focus; Side Effect Info Weighs Down Message

Executive Summary

Roche is developing a new direct-to-consumer advertising campaign using disease state and reminder ads to replace its initial product-and-use campaign for the weight loss agent Xenical.

You may also be interested in...



Disease Awareness Ad Guidance Stresses Need For “Distinct” Messages

The impact of FDA's draft guidance on disease awareness ads will depend upon how willing manufacturers are to allot portions of their advertising budgets to non-branded ads

Roche Xenical Patient Compliance Could Increase With New DTC Campaign

Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.

Roche Xenical Patient Compliance Could Increase With New DTC Campaign

Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel